- £1.92bn
- £993.52m
- $630.20m
- 17
- 44
- 72
- 37
RCS - Hutchmed China Ltd - Closing of Fruquintinib License to Takeda
AnnouncementREG - Hutchmed China Ltd - Director's Share Dealing
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under the LTIP
AnnouncementRCS - Hutchmed China Ltd - Publication of Form 20-F
AnnouncementREG - Hutchmed China Ltd - 2022 Full Year Results and Business Updates
AnnouncementRCS - Hutchmed China Ltd - Enrollment Completed in Phase 2 Amdizalisib trial
AnnouncementREG - Hutchmed China Ltd - Notice of Results
AnnouncementREG - Hutchmed China Ltd - License to Takeda for Fruquintinib outside China
AnnouncementREG - Hutchmed China Ltd - Inclusion of ORPATHYS in NRDL in China
AnnouncementRCS - Hutchmed China Ltd - Enrollment Completed in Phase 3 Trial
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
AnnouncementRCS - Hutchmed China Ltd - FDA NDA Rolling Submission for Fruquintinib
AnnouncementREG - Hutchmed China Ltd - HUTCHMED Announces Strategy Update
AnnouncementREG - Hutchmed China Ltd - Positive Topline Phase 3 Result in Fruquintinib
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Initiates Phase 2/3 Trial of Fruquintinib
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under the LTIP
AnnouncementRCS - Hutchmed China Ltd - Phase II/III Trial of Sovleplenib for in China
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - Share Option Scheme and Long Term Incentive Plan
Announcement